PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers
| Autor: | Fouad Al-Dayel, Hussah F AlHussaini, Sandeep Kumar Parvathareddy, Wael Haqawi, Maha Al-Rasheed, Khawla S Al-Kuraya, Padmanaban Annaiyappanaidu, Abdul K. Siraj, Hadeel Al-Manea |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
PD-L1
0301 basic medicine Oncology medicine.medical_specialty Poor prognosis Colorectal cancer lcsh:Medicine Medicine (miscellaneous) colorectal cancer Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine biology business.industry lcsh:R Retrospective cohort study Histology medicine.disease digestive system diseases Clinical trial mismatch repair 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Immunohistochemistry DNA mismatch repair prognosis business |
| Zdroj: | Journal of Personalized Medicine Volume 11 Issue 2 Journal of Personalized Medicine, Vol 11, Iss 73, p 73 (2021) |
| ISSN: | 2075-4426 |
| DOI: | 10.3390/jpm11020073 |
| Popis: | Several clinical trials are investigating the use of immune-targeted therapy with Programmed death ligand-1 (PD-L1) inhibitors for colorectal cancer (CRC), with promising results for patients with mismatch repair (MMR) deficiency or metastatic CRC. However, the prognostic significance of PD-L1 expression in CRC is controversial and such data are lacking in CRC from Middle Eastern ethnicity. We carried out this large retrospective study to investigate the prognostic and clinico-pathological impact of PD-L1 expression in Middle Eastern CRC using immunohistochemistry. A total of 1148 CRC were analyzed for PD-L1 expression. High PD-L1 expression was noted in 37.3% (428/1148) cases and was correlated with aggressive clinico-pathological features such as high malignancy grade (p < 0.0001), larger tumor size (p = 0.0007) and mucinous histology (p = 0.0005). Interestingly, PD-L1 expression was significantly higher in patients exhibiting MMR deficiency (p = 0.0169) and BRAF mutation (p = 0.0008). Furthermore, the expression of PD-L1 was found to be an independent marker for overall survival (HR = 1.45 95% CI = 1.06 &minus 1.99 p = 0.0200). In conclusion, the results of this study indicate that PD-L1 expression could be a valid biomarker for poor prognosis in Middle Eastern CRC patients. This information can help in decision-making for anti-PD-L1 therapy in Middle Eastern CRC, especially for patients with MMR deficient tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|